Abbott Laboratories
NYSE:ABTMedical - Devices
-$0.51 today
- Market cap
- $180.95B
- Beta
- 0.62
- P/E (TTM)
- 24.5
- EPS (TTM)
- $3.59
- Dividend yield
- 2.77%
Volume 7.02M
Average 13.17M
ABT Net Income
Bottom-line profit after all expenses, interest, and taxes.
Abbott LaboratoriesNYSE: ABT
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income declines year over year
Q3 FY2026 net income of $920M fell 44.0% year over year, ahead of the -66.4% change in trailing-twelve-month net income. Sequentially, it fell 0.9% from the prior quarter. Over 3 fiscal years it compounded at -2.0% a year.
Context
- Net income amounted to 14.7% of revenue in FY2025, down 17.2 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 20 analysts of $9.64B (+47.7%) for the fiscal year ending Dec 2026, a step up from the -51.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $920M-0.9% QoQ
- Last fiscal yearDec 2025
- $6.52B-51.3% YoY
- LTMSep 2026
- $4.7B-66.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -44.0% | +60.3% | +104.4 pp |
| 1 year | -51.3% | +47.7% | +99.0 pp |
| 3-year CAGR | -2.0% | +20.2% | +22.2 pp |
| 5-year CAGR | +16.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- 6.52B USD
- Year-over-year change
- -51.3%
- 4-year CAGR
- -2.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.52B | -51.3% |
| FY2024 | 2024-12-31 | 13.4B | +134.2% |
| FY2023 | 2023-12-31 | 5.72B | -17.5% |
| FY2022 | 2022-12-31 | 6.93B | -2.0% |
| FY2021 | 2021-12-31 | 7.07B | — |
Net Income vs competitors
How ABT compares with its peers on the latest reported figures
- ABT's LTM Sep 2026 net income of $4.7B is the 4th highest of the 10 companies compared; the peer median is $3.73B.
- Its year-over-year change of -66.4% is the 9th highest of 10, against a peer median of +7.8%.
- Net income amounts to 9.7% of revenue for ABT, versus a peer median of 15.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $16.1B | -35.9% | +14.3% | 16.2% | |
| LTM Sep 2026 | $7.08B | +7.8% | -1.0% | 15.0% | |
| LTM Jul 2026 | $5.23B | +12.2% | +8.5% | 13.9% | |
| LTM Sep 2026 | $4.7B | -66.4% | -2.0% | 9.7% | |
| LTM Sep 2026 | $4.33B | +23.6% | -20.6% | 16.9% | |
| LTM Jun 2026 | $3.73B | +27.8% | +11.2% | 14.4% | |
| LTM Jun 2026 | $3.67B | +46.6% | +60.5% | 17.5% | |
| LTM Jun 2026 | $1.59B | -29.0% | +2.8% | 7.9% | |
| LTM Sep 2026 | $1.14B | -31.8% | -8.3% | 5.7% | |
| LTM Jun 2026 | $1B | -75.8% | -11.0% | 15.4% | |
| Peer median (excluding ABT) | $3.73B | +7.8% | +2.8% | 15.0% | |
Competitors are the stored peer set for ABT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 43.08B | 43.65B | 40.11B | 41.95B | 44.33B |
| Cost of Revenue | 19.86B | 21.33B | 20.07B | 20.63B | 19.72B |
| Gross Profit | 23.21B | 22.32B | 20.04B | 21.33B | 24.61B |
| Gross Margin | 53.9% | 51.1% | 50.0% | 50.8% | 55.5% |
| Research & Development | 2.74B | 2.85B | 2.72B | 2.82B | 2.96B |
| Selling, General & Admin | 11.28B | 11.11B | 10.88B | 11.65B | 12.38B |
| Operating Expenses | 14.01B | 13.96B | 13.6B | 14.47B | 16.59B |
| Depreciation & Amortization | 3.54B | 3.27B | 3.24B | 3.22B | 3.12B |
| EBITDA | 12.16B | 11.89B | 10.61B | 10.83B | 11.92B |
| EBITDA Margin | 28.2% | 27.2% | 26.4% | 25.8% | 26.9% |
| Operating Income | 9.2B | 8.36B | 6.44B | 6.83B | 8.05B |
| Operating Margin | 21.4% | 19.2% | 16.0% | 16.3% | 18.2% |
| Interest Income | 43M | 183M | 385M | 344M | 230M |
| Interest Expense | 410M | 315M | 698M | 603M | 341M |
| Other Income / Expenses | (989M) | (56M) | 229M | 188M | 418M |
| Income Before Tax | 8.21B | 8.31B | 6.66B | 7.01B | 8.47B |
| Pre-Tax Margin | 19.1% | 19.0% | 16.6% | 16.7% | 19.1% |
| Income Tax Expense | 1.14B | 1.37B | 941M | (6.39B) | 1.94B |
| Net Income | 7.07B | 6.93B | 5.72B | 13.4B | 6.52B |
| Net Margin | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% |
| EPS (Basic) | 3.97 | 3.94 | 3.30 | 7.67 | 3.74 |
| EPS (Diluted) | 3.94 | 3.91 | 3.27 | 7.64 | 3.72 |
| Weighted Avg Shares | 1.78B | 1.75B | 1.73B | 1.73B | 1.75B |
| Weighted Avg Shares (Diluted) | 1.79B | 1.76B | 1.75B | 1.75B | 1.75B |
Abbott Laboratories
NYSE:ABT
Intrinsic Alpha fair value
Locked
Current Price
$104.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.